Introduction
Brain function is based on precise neuronal-network formation during development, which is largely controlled by attractive and repulsive axon-guidance molecules [1] . The spatially and temporally regulated expression of the guidance cues navigates the outgrowth of axons and specifies their termination zones and synaptic partners [2, 3] . Many guidance molecules persist in the adult central nervous system and extensive studies have shown that these factors have roles in maintenance and plasticity of neural circuits [4] . Such factors also participate in adult brain repair and regeneration after brain injury [4] . Emerging evidence indicates that guidance molecules could also have important roles in neurodegenerative disorders owing to altered signaling during development and/or owing to altered maintenance of synaptic connections in the adult. There is some neuropathological evidence of misrouted fibers in the adult human brain, and in Parkinson disease (PD) and Alzheimer's disease [5] .
PD is primarily a movement disorder characterized by resting tremor, bradykinesia, rigidity and postural instability. The pathological underpinnings of these motor symptoms include a marked degeneration of dopamine (DA) neurons in the substantia nigra (SN), with resultant striatal DA deficiency. The lifetime risk for PD in the general population is 2% [6] and the incidence of PD rises steeply with age [7] . Presently, there is no method of preventing PD or of halting its progression. However, a method of predicting PD was recently reported [8] . This genomic pathway approach involved measuring common variations (single-nucleotide polymorphisms [SNPs]) within a family of genes that encode the wiring of the brain during fetal development and that encode the maintenance and repair of brain wiring throughout life (the axon-guidance pathway). The additive effects of these variants (SNP models) were highly predictive of PD susceptibility, survival free of PD and age at onset of PD in two independent genome-wide association (GWA) datasets. Several axon-guidance-pathway genes represented by SNPs in the predictive models were differentially expressed in a genome-wide expression profiling dataset. SNP models for PD were subsequently refined and compared with axon-guidance-pathway SNP models that were highly predictive of amyotrophic lateral sclerosis (ALS) [9] . Distinct gene signatures for the two diseases were defined within the pathway, and ultimately these diseases could be predicted with >90% sensitivity and specificity. However, the findings for the axon-guidance pathway and ALS await validation in a second GWA dataset.
Here, we summarize axon-guidance-pathway SNP models for PD outcomes in two GWA datasets and also describe the roles and mechanisms involved in the actions of these specific axon-guidance-pathway genes or gene products as candidate targets for neuroprotective therapies. We also summarize experimental data for PD, relevant DA neurons and their connected target neurons as rationales for these therapeutic targets.
Axon-guidance-pathway SNP models nominate therapeutic targets for PD A GWA study of PD mapped the semaphorin 5A (SEMA5A) gene as a susceptibility locus for PD [10] and, thus, high- 
